• Publications
  • Influence
Ondansetron Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder
TLDR
Results suggest that low-dose ondansetron may have promise as an augmentation strategy for some patients with OCD resistant to SSRIs and antipsychotic augmentation, but further controlled trials are required. Expand
Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following
TLDR
OCD patients who do not adequately respond to an SRI may benefit from augmentation with a low-dose of ondansetron, which may provide an alternative approach to augmented with atypical antipsychotic agents, with a more favorable safety profile. Expand
Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover
TLDR
The initial rate of absorption was faster, and initial systemic exposure was greater, with ZST compared with oral IR, and systemic exposure of zolpidem was higher in females for both formulations. Expand
Pharmacokinetics of Ibuprofen Enantiomers in Humans Following Oral Administration of Tablets with Different Absorption Rates
TLDR
The extent of R-to-S inversion, and hence the potency of a racemic dose of IB, may be absorption rate dependent. Expand
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration
TLDR
It is confirmed that zolpidem clearance is lower in females than in males, and PD effects of zolPidem from ZST are greater in female subjects, due to a combination of higher plasma concentrations and greater intrinsic sensitivity. Expand
Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient
TLDR
3.5 mg ZST used as needed significantly reduced latency to return to sleep in comparison with placebo in these patients with insomnia, and sleep quality was improved, and morning sleepiness/alertness scores also improved. Expand
Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate
TLDR
This double‐blind placebo‐controlled cross‐over study evaluated the pharmacokinetics and daytime‐sedative profile of 1.0, 1.75, and 3.5 mg dose of the ST zolpidem formulation for the treatment of middle‐of‐the‐night insomnia. Expand
Pharmacokinetics of Zolpidem from Sublingual Zolpidem Tartrate Tablets In Healthy Elderly Versus Non-Elderly Subjects
TLDR
Elderly individuals were found to have higher Cmax and AUC values compared with non-elderly subjects and area under the plasma concentration–time curve (AUC), maximum observed concentration (Cmax), time to reach Cmax, elimination half-life (T½), and apparent oral clearance (CL/F). Expand
Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets
TLDR
It is suggested that administration of ZST in the fed state is not optimal for maximizing the likelihood of therapeutic benefit and minimizing the probability of residual sedation. Expand
Gender influences on efficacy and safety of sublingual zolpidem tartrate for middle‐of‐the‐night awakening in insomnia
TLDR
Evaluate potential gender effects on efficacy and safety of a buffered zolpidem sublingual tablet (ZST) formulation and determine if this formulation is suitable for use in women and men. Expand
...
1
2
3
...